Deflexifol

FivepHusion - Optimised Cancer Therapeutics

FivepHusion is developing Deflexifol™, a novel drug formulation created to address oncologists' needs for safer and more efficacious anti-cancer therapy.

Deflexifol® at Relapse Trial (DART) - Australian & New Zealand ...

The DART study is a Phase I/II study of Deflexifol®, a co-formulation of a chemotherapy called 5-FU and leucovorin, and is expected to be less toxic and more ...

Deflexifol™ Clinical Data Presented at the 2024 ... - FivepHusion

FivepHusion (www.fivepHusion.com) is an advanced clinical-stage, globally focused biotechnology company whose purpose is to optimise chemotherapy.

Deflexifol (a novel formulation of 5FU): Phase 1 dose escalation ...

Deflexifol has little toxicity and is effective in bolus and infusion schedules at doses equal to or greater than those feasible with 5FU and LV infused ...

First-in-human phase I study of infusional and bolus schedules of ...

Deflexifol is safer and effective in bolus and infusion schedules at higher doses than that permitted by separate infusion of 5-FU and LV. A phase II study ...

Chemotherapy drug development - UOW Research Impact

Researchers at UOW developed a new chemotherapy, Deflexifol, which overcomes the problems of severe adverse side effects associated with existing treatments.

Deflexifol (a novel formulation of 5FU): Pharmacokinetics in a phase ...

Conclusions: 5FU PK with Deflexifol is similar to 5FU alone. No evidence of saturation of kinetics over this dose range was seen, or induction of metabolism ...

Allarity Therapeutics and FivepHusion Announce Collaboration to ...

Deflexifol™ is a novel anti-cancer drug reformulation designed to address the safety and efficacy limitations of standard-of-care 5FU chemotherapy. It combines, ...

FivepHusion announces ethics approval of Phase 1b trial of ...

Deflexifol is an an optimised all-in-one formulation of the chemotherapeutic agent 5-fluorouracil (5-FU) and its biomodulator leucovorin (LV), ...

World first clinical trial for childhood Ependymoma

Deflexifol® is a new Australian-developed co-formulation of a chemotherapy drug called 5-FU and leucovorin. 5-FU has been effective in the past ...

First patient enrolled in Deflexifol® At Relapse Trial (DART) - anzchog

The DART Study is investigating Deflexifol® as a promising new treatment for ependymoma and other paediatric brain cancers. Deflexifol® is a new Australian- ...

World-first trial for paediatric brain cancer right here in NSW

A world-first clinical trial, known as The Deflexifol® At Relapse Trial (DART), proudly supported by Kids with Cancer Foundation, ...

Trial Review - ANZCTR - Registration

This is a phase I multicentre study evaluating the use of Deflexifol in the treatment of children and young adults (greater than 12 months and less than or ...

Customer insight: Scaling success through close cooperation

Deflexifol™ is an optimized all-in-one formulation of 5-FU and LV which facilitates, for the first time, the simultaneous administration of these chemically ...

FivepHusion Reach Milestone in Deflexifol™ Clinical Trial

FivepHusion Reach Milestone in Deflexifol™ Clinical Trial ... Treatment has commenced for the initial patient in the Deflexifol™ at Relapse Trial ...

We'll stop at nothing to help prevent and treat cancer

FivepHusion's new drug, 'Deflexifol™, addresses significant limitations in current treatment for solid tumour cancer patients and aims to improve patient ...

Allarity Therapeutics and FivepHusion Announce Collaboration to ...

Deflexifol™ is a novel anti-cancer drug reformulation designed to address the safety and efficacy limitations of standard-of-care 5FU ...

FivepHusion collaborates with Treehill, Syneos for Deflexifol

FivepHusion has collaborated with Treehill Partners and Syneos Health to strategically progress development and commercialisation of its ...

Deflexifol clinical data presented at ASCO Gastrointestinal Cancers ...

FivepHusion has announced that a poster of the most recently completed deflexifol clinical trial was presented at the American Society of ...

FivepHusion Gets Ethics Nod for Phase 1b Trial of Deflexifol

The trial design is based on US FDA advice. It will be the fourth clinical study investigating Deflexifol as a treatment for solid tumours and ...